

Amendments to the Claims

Claims 1-24 (Cancelled).

25. (Currently amended) A composition for delivery of superoxide dismutase (SOD) to neuronal cells, comprising SOD₂; linked by a cleavable linker to a neuronal cell targeting component, wherein said neuronal cell targeting component comprises a first domain that binds to a neuronal cell and a second domain that translocates the SOD of the composition into the neuronal cell, and wherein said cleavable linker is selected from the group consisting of (a) a disulfide bridge, and (b) a site for a protease found in neuronal cells.

26. (Cancelled).

27. (Cancelled).

28. (Cancelled).

29. (Previously presented). The composition of claim 25 wherein the SOD is bacterial SOD or is derived therefrom.

30. (Currently amended). The composition of claim 25 wherein the first domain is selected from the group consisting of

~~(a) neuronal cell binding domains of clostridial toxins; and~~

~~(b) fragments, variants and derivatives of the domains in (a) that substantially retain the neuronal cell binding activity of the domains of (a).~~

31. (Currently amended) The composition of claim 30 wherein the second domain is selected from the group consisting of

(a) domains of clostridial neurotoxins that translocate polypeptide sequences into cells, ~~and~~

~~(b) fragments, variants and derivatives of the domains of (a) that substantially retain the translocating activity of the domains of (a).~~

32. (Previously presented) The composition of claim 25 wherein the linker is a disulphide bridge.

33. (Currently amended) A ~~pharmaceutical~~ composition for treatment of oxidative damage to neuronal cells comprising the composition of claim 25 and a pharmaceutically acceptable carrier.

34. (Cancelled).

35. (Cancelled).

36. (Currently amended) A composition for delivery of an agent ~~a therapeutic agent~~ to neuronal cells, comprising the ~~therapeutic agent~~, linked by a cleavable linker to a neuronal cell targeting component, wherein said neuronal cell targeting component comprises a first domain that binds to a neuronal cell and a second domain that translocates the ~~therapeutic agent~~ of the composition into the neuronal cell, and wherein said cleavable linker is a disulfide bridge.

37. (Cancelled).

38. (Cancelled).

39. (Cancelled).

40. (Cancelled).

41. (Cancelled).

42. (Previously presented) The composition of claim 25 wherein the cleavable linker is a disulphide bridge between first and second cysteine residues, wherein said first cysteine residue is on the SOD and said second cysteine residue is on the neuronal cell targeting component.

43. (Previously presented) The composition of claim 25 wherein the cleavable linker is a site for a protease found in neuronal cells.

This listing of claims will replace all prior versions, and listings of claims in the application.